debrisoquin and 10-hydroxynortriptyline

debrisoquin has been researched along with 10-hydroxynortriptyline in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (40.00)	18.7374
1990's	2 (40.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baumann, P; Jonzier-Perey, M; Koeb, L; Küpfer, A; Schöpf, J; Tinguely, D	1
Benitez, J; Bertilsson, L; Nordin, C; Siwers, B	1
Gu, NF; Jiang, WD; Yin, JL; Yu, P; Zhang, XH	1
Bertilsson, L; Dahl, ML; Nordin, C	1
Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J	1

Trials

2 trial(s) available for debrisoquin and 10-hydroxynortriptyline

Article	Year
Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology, 1996, Volume: 123, Issue:4 Topics: Adult; Aged; Alleles; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Debrisoquin; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Nortriptyline; Polymerase Chain Reaction; Regression Analysis	1996
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia	2001

Article

Year

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.

Psychopharmacology, 1996, Volume: 123, Issue:4

Topics: Adult; Aged; Alleles; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Debrisoquin; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Nortriptyline; Polymerase Chain Reaction; Regression Analysis

1996

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:4

Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia

2001

Other Studies

3 other study(ies) available for debrisoquin and 10-hydroxynortriptyline

Article	Year
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. International clinical psychopharmacology, 1986, Volume: 1, Issue:2 Topics: Adult; Amitriptyline; Debrisoquin; Depressive Disorder; Female; Humans; Hydantoins; Hydroxylation; Isoquinolines; Kinetics; Male; Mephenytoin; Middle Aged; Nortriptyline; Phenotype; Polymorphism, Genetic	1986
Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. British journal of clinical pharmacology, 1985, Volume: 19, Issue:6 Topics: Debrisoquin; Depressive Disorder; Humans; Hydroxylation; Isoquinolines; Nortriptyline	1985
[Relationship between amitriptyline metabolism and polymorphic debrisoquine hydroxylation in native Chinese volunteers]. Yao xue xue bao = Acta pharmaceutica Sinica, 1993, Volume: 28, Issue:2 Topics: Adult; Amitriptyline; Asian People; Debrisoquin; Humans; Hydroxylation; Male; Metabolic Clearance Rate; Nortriptyline; Phenotype; Polymorphism, Genetic; Species Specificity	1993